CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr | ₹1,547 Cr |
What is the latest Consolidated Net Profit of CIPLA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹4,122 Cr |
| Mar2024 | ₹2,802 Cr |
| Mar2023 | ₹2,517 Cr |
| Mar2022 | ₹2,405 Cr |
| Mar2021 | ₹1,547 Cr |
How is Consolidated Net Profit of CIPLA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | 55.50 | |
| Mar2021 | ₹1,547 Cr | - | |
Compare Consolidated Net Profit of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹127,951.5 Cr | -3.4% | 3% | 4.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,471.0 Cr | 0.3% | 4.1% | -9.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,294.0 Cr | -1.7% | 8.5% | 13.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,691.0 Cr | 0.7% | -0.5% | 7.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,214.0 Cr | 0.2% | -1.1% | -3.6% | Stock Analytics | |
| MANKIND PHARMA | ₹99,677.0 Cr | -1.6% | -4.5% | -5.3% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -3.4% |
3% |
4.8% |
| SENSEX | 1% |
3.3% |
4.5% |
You may also like the below Video Courses